BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1754 related articles for article (PubMed ID: 16224390)

  • 21. Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.
    Taketomi T; Szlam F; Bader SO; Sheppard CA; Levy JH; Tanaka KA
    Blood Coagul Fibrinolysis; 2008 Mar; 19(2):135-41. PubMed ID: 18277134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII.
    Liebman HA; Chediak J; Fink KI; Galvez AG; Shah PC; Sham RL
    Am J Hematol; 2000 Mar; 63(3):109-13. PubMed ID: 10679799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent.
    Hedner U; Brun NC
    Neuroradiology; 2007 Oct; 49(10):789-93. PubMed ID: 17653706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
    Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M
    Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experiences with recombinant human factor VIIa in patients with thrombocytopenia.
    Goodnough LT
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):25-9. PubMed ID: 14872417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant factor VIIa in the treatment of bleeding.
    Midathada MV; Mehta P; Waner M; Fink LM
    Am J Clin Pathol; 2004 Jan; 121(1):124-37. PubMed ID: 14750250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies.
    Hedner U
    Thromb Haemost; 2008 Oct; 100(4):557-62. PubMed ID: 18841276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. History of rFVIIa therapy.
    Hedner U
    Thromb Res; 2010 Apr; 125 Suppl 1():S4-6. PubMed ID: 20188400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
    Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
    J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant factor VIIa: a review on its clinical use.
    Franchini M
    Int J Hematol; 2006 Feb; 83(2):126-38. PubMed ID: 16513530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?
    Poon MC
    Curr Hematol Rep; 2003 Mar; 2(2):139-47. PubMed ID: 12901145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
    Hoffman M; Monroe DM
    Dis Mon; 2003 Jan; 49(1):14-21. PubMed ID: 12525825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.
    Antovic JP; Antovic A; He S; Tengborn L; Blombäck M
    Haemophilia; 2002 Nov; 8(6):781-6. PubMed ID: 12410647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant activated factor VII (rFVIIa): characterization, manufacturing, and clinical development.
    Jurlander B; Thim L; Klausen NK; Persson E; Kjalke M; Rexen P; Jørgensen TB; Østergaard PB; Erhardtsen E; Bjørn SE
    Semin Thromb Hemost; 2001 Aug; 27(4):373-84. PubMed ID: 11547359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Further understanding of recombinant activated factor VII mode of action.
    Monroe DM
    Semin Hematol; 2008 Apr; 45(2 Suppl 1):S7-S11. PubMed ID: 18544430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma.
    Martinowitz U; Kenet G; Lubetski A; Luboshitz J; Segal E
    Can J Anaesth; 2002 Dec; 49(10):S15-20. PubMed ID: 12546003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First 20 years with recombinant FVIIa (NovoSeven).
    Hedner U; Lee CA
    Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The emerging role of recombinant-activated factor VII in neurocritical care.
    Fewel ME; Park P
    Neurocrit Care; 2004; 1(1):19-29. PubMed ID: 16174895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of recombinant activated coagulation factor VII for spine surgery.
    Weiskopf RB
    Eur Spine J; 2004 Oct; 13 Suppl 1(Suppl 1):S83-8. PubMed ID: 15160317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet-dependent thrombin generation assay for monitoring the efficacy of recombinant Factor VIIa.
    Wegert W; Harder S; Bassus S; Kirchmaier CM
    Platelets; 2005 Feb; 16(1):45-50. PubMed ID: 15763896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 88.